Fatigue numeric rating scale validity, discrimination and responder definition in patients with psoriatic arthritis.
Dafna Gladman, Peter Nash, Hitoshi Goto...
https://pubmed.ncbi.nlm.nih.gov/31958274/Actively Recruiting
Led by Larimar Therapeutics, Inc. · Updated on 2026-10-09
150
Participants Needed
4
Research Sites
21 weeks
Total Duration
Researchers are evaluating the efficacy and safety of subcutaneous nomlabofusp in both adult and pediatric subjects with Friedreichs ataxia, a genetic condition. This is a global, randomized, multi-center, placebo-controlled Phase 3 study that aims to assess how nomlabofusp affects balance and overall disease severity compared to placebo over a period of 72 weeks. Participants will receive either a daily subcutaneous injection of nomlabofusp or a placebo for 72 weeks. The study includes two groups one receiving the active drug and the other receiving placebo injections. The study will measure changes in balance using the Upright Stability Score USS subscale E of the modified Friedreichs Ataxia Rating Scale mFARS and the total mFARS score, as well as the Clinical Global Impression of Severity CGI-S at multiple time points through Week 72. During the study, participants will undergo regular assessments at baseline and Weeks 12, 24, 36, 48, and 72. These evaluations include clinical scales measuring balance and disease severity. Safety and tolerability of nomlabofusp will also be monitored throughout. Participants must meet specific eligibility criteria including genetic confirmation of Friedreichs ataxia, performance on stability tests, and functional staging. The total duration of participation spans the 72-week treatment period with scheduled evaluations.
CONDITIONS
A Study to Evaluate the Efficacy and Safety of Subcutaneous Nomlabofusp in Subjects With Friedreich's Ataxia
L
Larimar Therapeutics, Inc.
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
Larimar Therapeutics, Inc.
Lead Sponsor
This table compares participation in this trial with other options available for this condition. The information is drawn from published research and the trial’s study details and is provided for educational purposes only.
| Factors | Nomlabofusp (SC) | Placebo (SC) | Omaveloxolone (oral, FDA‑approved) |
|---|---|---|---|
| What the treatment is | A recombinant fusion protein delivering human frataxin by subcutaneous injection | Sterile subcutaneous injection matching placebo | Approved oral small‑molecule Nrf2 activator (SKYCLARYS™) that modifies disease course in Friedreich’s ataxia |
| Role in the study | Investigational therapy under evaluation | Randomized placebo comparator | Current approved treatment outside of trial |
| Primary intended benefit | To replace deficient frataxin in individuals with Friedreich’s ataxia | No active therapeutic benefit; serves as control | Activates cellular stress response pathways to slow neurological progression |
| Administration | Daily subcutaneous injection self‑administered or by caregiver | Daily subcutaneous injection matched placebo | Once‑daily oral tablet |
| Evidence supporting use | Efficacy under evaluation in this phase III randomized trial; no published results yet | Used as inert control; no efficacy evidence | Clinical trials and guidelines support evidence that omaveloxolone slows progression of neurological decline |
| Known important risks | Not yet established; safety data pending trial results | Risks align with injection‑related effects but placebo contains no active drug | Potential side effects identified in trials include elevated liver enzymes and headache |
| Important limitations | No efficacy or safety data available yet; long‑term effects unknown | Placebo provides no therapeutic benefit and does not represent any standard treatment | Applicable only to patients aged 16 years and older; long‑term effects and applicability to younger patients may differ |
Disclaimer: This comparison is created with the help of artificial intelligence(AI) and may contain errors or missing information. It is not medical advice and does not mean one option is better or safer than another. Clinical trials are still being studied, and joining a trial is your choice. Please consult your healthcare professional before making any decisions.
You may qualify if you...
You will not qualify if you...
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
Duration - 72 weeks
Participants receive daily subcutaneous injections of either nomlabofusp or placebo for 72 weeks.
Visits at baseline and Weeks 12, 24, 36, 48, and 72
Study Type
INTERVENTIONAL
Masking
QUADRUPLE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Have more questions? Get in touch with our team for quick support
Dafna Gladman, Peter Nash, Hitoshi Goto...
https://pubmed.ncbi.nlm.nih.gov/31958274/Elisabetta Indelicato, Wolfgang Nachbauer, Andreas Eigentler...
https://pubmed.ncbi.nlm.nih.gov/32746884/Arnulf H Koeppen
https://pubmed.ncbi.nlm.nih.gov/21315377/R Daniel Meyer, Bohdana Ratitch, Marcel Wolbers...
https://pubmed.ncbi.nlm.nih.gov/34191971/Michael Lazaropoulos, Yina Dong, Elisia Clark...
https://pubmed.ncbi.nlm.nih.gov/26339677/R Rudick, J Antel, C Confavreux...
https://pubmed.ncbi.nlm.nih.gov/8797541/Yongming Qu, Biyue Dai
https://pubmed.ncbi.nlm.nih.gov/34985825/J D Fisk, P G Ritvo, L Ross...
https://pubmed.ncbi.nlm.nih.gov/8148458/D E Goodkin, D Hertsgaard, J Seminary
https://pubmed.ncbi.nlm.nih.gov/3178453/R Little, L Yau
https://pubmed.ncbi.nlm.nih.gov/8962456/Larimar Therapeutics, Inc.
Lead Sponsor